BEONE MEDICINES UK, LTD.
Get an alert when BEONE MEDICINES UK, LTD. files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-04 (in 5mo)
Last made up 2025-09-20
Watchouts
Cash
£3M
+670.7% vs 2023
Net assets
£504M
+25.4% vs 2023
Employees
58
+26.1% vs 2023
Profit before tax
-£2M
-104% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Outstanding charges registered
One or more mortgages or charges remain undischarged on the Companies House register.
Name history
Renamed 1 time since incorporation
- BEONE MEDICINES UK, LTD. 2025-05-12 → present
- BEIGENE UK, LTD. 2018-12-14 → 2025-05-12
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £16,747,340 | £31,438,817 | |
| Operating profit | -£951,681 | -£1,928,900 | |
| Profit before tax | -£941,595 | -£1,920,945 | |
| Net profit | -£1,276,372 | -£3,222,114 | |
| Cash | £343,437 | £2,646,941 | |
| Total assets less current liabilities | £401,632,114 | £503,755,320 | |
| Net assets | £401,632,014 | £503,755,220 | |
| Equity | £401,632,014 | £503,755,220 | |
| Average employees | 46 | 58 | |
| Wages | £7,314,327 | £8,666,970 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -5.7% | -6.1% | |
| Net margin | -7.6% | -10.2% | |
| Return on capital employed | -0.2% | -0.4% | |
| Current ratio | 1.73x | 0.82x | |
| Interest cover | — | -5809.94x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The company made an operating loss of £1.9m in the financial year and is therefore reliant on the support of its parent company. The Company undertakes business mainly for the related companies. The likelihood of cessation of the arrangement is very low and the directors do not see any significant business risk or uncertainty. Furthermore, a parent letter of support has been provided by BeOne Medicines Ltd, formerly Beigene Ltd, until 31 December 2026. The directors have considered the financial resources with the support from the ultimate parent undertaking and are satisfied that the parent company can provide support.. The directors, having made appropriate enquiries, are satisfied that the parent company is capable of providing the support if required. Accordingly, the financial statements have been prepared on the going concern basis..”
Group structure
- BEONE MEDICINES UK, LTD. · parent
- BeiGene Korea Y.H. 100%
- BeOne Switzerland Gmbh 100%
- BeiGene Australia 100%
- BeOne Medicines United Kingdom Ltd 100%
- BeiGene US Holdings, LLC 100%
- BeiGene Japan, Ltd 100%
- BeiGene Brasil Ltda. 100%
- BeOne Medicines Ireland Limited 100%
- Beigene Turkey Tibbi Ürünler Ticaret Limited Şirketi 100%
- BeiGene Pharmaceuticals Israel Ltd. 100%
- BeiGene Singapore Pte. Ltd. 100%
- BeiGene (Thailand) Ltd. 99.98%
- BeiGene Malaysia Sdn. Bhd. 100%
- BeiGene Argentina S.R.L. 95.28%
- BeiGene Colombia S.A.S. 100%
- BeiGene Chile Limitada 100%
- BeiGene Mexico S. de R.L. de C.V. 95%
- BeiGene South Africa Pty Ltd. 100%
- BeiGene Peru (Sociedad Comercial de Responsabilidad Limitada – S.R.L) 95%
- BG NC 1, Ltd. 95%
Significant events
- “On 16 January 2025, the directors proposed that the share premium account be cancelled and the £275,084,152 balance be credited to a distributable reserve.”
- “Also subsequent to the balance sheet date, additional capital contributions were made to BeiGene Malaysia ($250,000), BeiGene Colombia ($200,000) and BeiGene Peru ($80,000).”
- “BG NC 1, Ltd. repaid a loan granted by the Parent Company and ceases to be a subsidiary.”
- “D Dusoruth resigned on 21 February 2025.”
- “The company has changed its name from BeiGene UK, Ltd. to BeOne Medicines UK, Ltd. as of 12th May 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HARRIS, James Edwards | Director | 2024-08-01 | Oct 1979 | British |
| MULROONEY, Robert Dominic | Director | 2021-10-19 | Apr 1961 | Irish |
| NAVEN, Jeffrey William | Director | 2025-12-18 | Feb 1964 | American |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DUSORUTH, Devun | Director | 2022-08-31 | 2025-02-21 |
| LIANG, Howard | Director | 2018-12-14 | 2021-05-31 |
| SAMUELS, Scott Alan | Director | 2018-12-14 | 2022-06-30 |
| WANG, Aijun | Director | 2021-05-31 | 2022-09-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Beone Medicines Ltd. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-12-14 | Active |
Filing timeline
Last 20 of 61 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-05-12 CERTNM Certificate change of name company PDF
- 2025-01-21 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-27 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-12-18 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-24 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-10-27 | AA | accounts | Accounts with accounts type full | |
| 2025-10-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-07-02 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-05-12 | CERTNM | change-of-name | Certificate change of name company | |
| 2025-03-04 | TM01 | officers | Termination director company with name termination date | |
| 2025-01-21 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-01-21 | SH20 | capital | Legacy | |
| 2025-01-21 | CAP-SS | insolvency | Legacy | |
| 2025-01-21 | RESOLUTIONS | resolution | Resolution | |
| 2024-10-12 | AA | accounts | Accounts with accounts type full | |
| 2024-09-27 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-01 | AP01 | officers | Appoint person director company with name date | |
| 2024-06-10 | SH01 | capital | Capital allotment shares | |
| 2024-05-14 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2024-04-17 | SH01 | capital | Capital allotment shares | |
| 2024-04-02 | SH01 | capital | Capital allotment shares | |
| 2024-03-19 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 7
- Capital events
- 4
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+87.7%
£16,747,340 £31,438,817
-
Cash
+670.7%
£343,437 £2,646,941
-
Net assets
+25.4%
£401,632,014 £503,755,220
-
Employees
+26.1%
46 58
-
Operating profit
-102.7%
-£951,681 -£1,928,900
-
Profit before tax
-104%
-£941,595 -£1,920,945
-
Wages
+18.5%
£7,314,327 £8,666,970
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers